These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23024015)

  • 41. Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab.
    Braun J; Baraliakos X; Hermann KG; Xu S; Hsu B
    J Rheumatol; 2016 May; 43(5):901-6. PubMed ID: 26932345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study.
    Carron P; Varkas G; Cypers H; Van Praet L; Elewaut D; Van den Bosch F;
    Ann Rheum Dis; 2017 Aug; 76(8):1389-1395. PubMed ID: 28213565
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study).
    Navarro-Sarabia F; Fernández-Sueiro JL; Torre-Alonso JC; Gratacos J; Queiro R; Gonzalez C; Loza E; Linares L; Zarco P; Juanola X; Román-Ivorra J; Martín-Mola E; Sanmartí R; Mulero J; Diaz G; Armendáriz Y; Collantes E
    Rheumatology (Oxford); 2011 Oct; 50(10):1828-37. PubMed ID: 21700683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
    Marzo-Ortega H; McGonagle D; Jarrett S; Haugeberg G; Hensor E; O'connor P; Tan AL; Conaghan PG; Greenstein A; Emery P
    Ann Rheum Dis; 2005 Nov; 64(11):1568-75. PubMed ID: 15829577
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Lambert RG; Salonen D; Rahman P; Inman RD; Wong RL; Einstein SG; Thomson GT; Beaulieu A; Choquette D; Maksymowych WP
    Arthritis Rheum; 2007 Dec; 56(12):4005-14. PubMed ID: 18050198
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monitoring Achilles enthesitis in ankylosing spondylitis during TNF-alpha antagonist therapy: an ultrasound study.
    Aydin SZ; Karadag O; Filippucci E; Atagunduz P; Akdogan A; Kalyoncu U; Grassi W; Direskeneli H
    Rheumatology (Oxford); 2010 Mar; 49(3):578-82. PubMed ID: 20040527
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J; Sieper J; Weiß A; Zink A; Listing J
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
    Keystone EC; Genovese MC; Hall S; Miranda PC; Bae SC; Palmer W; Wu Z; Xu S; Hsia EC
    J Rheumatol; 2013 Jul; 40(7):1097-103. PubMed ID: 23678153
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab.
    Mease PJ; Van den Bosch F; Sieper J; Xia Y; Pangan AL; Song IH
    J Rheumatol; 2017 May; 44(5):599-608. PubMed ID: 28298558
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.
    Wenzel SE; Barnes PJ; Bleecker ER; Bousquet J; Busse W; Dahlén SE; Holgate ST; Meyers DA; Rabe KF; Antczak A; Baker J; Horvath I; Mark Z; Bernstein D; Kerwin E; Schlenker-Herceg R; Lo KH; Watt R; Barnathan ES; Chanez P;
    Am J Respir Crit Care Med; 2009 Apr; 179(7):549-58. PubMed ID: 19136369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.
    van der Heijde D; Landewé R; Baraliakos X; Houben H; van Tubergen A; Williamson P; Xu W; Baker D; Goldstein N; Braun J;
    Arthritis Rheum; 2008 Oct; 58(10):3063-70. PubMed ID: 18821688
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) - an open-label randomized controlled multicenter trial.
    Proft F; Muche B; Listing J; Rios-Rodriguez V; Sieper J; Poddubnyy D
    BMJ Open; 2017 Jun; 7(6):e014591. PubMed ID: 28601821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
    Taylor PC; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Mack M; Kremer J
    J Rheumatol; 2011 Dec; 38(12):2572-80. PubMed ID: 22089463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
    Revicki DA; Luo MP; Wordsworth P; Wong RL; Chen N; Davis JC;
    J Rheumatol; 2008 Jul; 35(7):1346-53. PubMed ID: 18484692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.
    Braun J; Deodhar A; Dijkmans B; Geusens P; Sieper J; Williamson P; Xu W; Visvanathan S; Baker D; Goldstein N; van der Heijde D;
    Arthritis Rheum; 2008 Sep; 59(9):1270-8. PubMed ID: 18759257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.